156 related articles for article (PubMed ID: 31863596)
1. Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance.
Rozga P; Kloska D; Pawlak S; Teska-Kaminska M; Galazka M; Bukato K; Pieczykolan A; Jaworski A; Molga-Kaczmarska A; Kopacz A; Badyra B; Kachamakova-Trojanowska N; Zolnierkiewicz O; Targosz-Korecka M; Poleszak K; Szymanik M; Zerek B; Pieczykolan J; Jozkowicz A; Grochot-Przeczek A
Int J Cancer; 2020 Aug; 147(4):1117-1130. PubMed ID: 31863596
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models.
Kopczynski M; Statkiewicz M; Cybulska M; Kuklinska U; Unrug-Bielawska K; Sandowska-Markiewicz Z; Grochowska A; Gajewska M; Kulecka M; Ostrowski J; Mikula M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808900
[TBL] [Abstract][Full Text] [Related]
3. Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma.
Piechna K; Żołyniak A; Jabłońska E; Noyszewska-Kania M; Szydłowski M; Żerek B; Kulecka M; Rumieńczyk I; Mikula M; Juszczyński P
Front Oncol; 2022; 12():1048741. PubMed ID: 36387080
[TBL] [Abstract][Full Text] [Related]
4. AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.
Pieczykolan JS; Kubiński K; Masłyk M; Pawlak SD; Pieczykolan A; Rózga PK; Szymanik M; Gałązka M; Teska-Kamińska M; Żerek B; Bukato K; Poleszak K; Jaworski A; Strożek W; Świder R; Zieliński R
Invest New Drugs; 2014 Dec; 32(6):1155-66. PubMed ID: 25182378
[TBL] [Abstract][Full Text] [Related]
5. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy.
Qiu F; Hu M; Tang B; Liu X; Zhuang H; Yang J; Hua ZC
Sci Rep; 2013 Dec; 3():3565. PubMed ID: 24356445
[TBL] [Abstract][Full Text] [Related]
6. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
7. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
[TBL] [Abstract][Full Text] [Related]
8. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
10. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
11. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
12. Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells.
Rozanov DV; Savinov AY; Golubkov VS; Rozanova OL; Postnova TI; Sergienko EA; Vasile S; Aleshin AE; Rega MF; Pellecchia M; Strongin AY
Mol Cancer Ther; 2009 Jun; 8(6):1515-25. PubMed ID: 19509255
[TBL] [Abstract][Full Text] [Related]
13. TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers.
Wang Y; Lei Q; Yan Z; Shen C; Wang N
Biochem Pharmacol; 2018 Sep; 155():510-523. PubMed ID: 30059675
[TBL] [Abstract][Full Text] [Related]
14. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
[TBL] [Abstract][Full Text] [Related]
15. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.
Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W
Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258
[TBL] [Abstract][Full Text] [Related]
17. GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial.
Jiang J; Liu X; Deng L; Zhang P; Wang G; Wang S; Liu H; Su Y
Eur J Pharmacol; 2014 Oct; 740():722-32. PubMed ID: 24929054
[TBL] [Abstract][Full Text] [Related]
18. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
19. A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo.
Rozanov D; Spellman P; Savinov A; Strongin AY
PLoS One; 2015; 10(4):e0122980. PubMed ID: 25849628
[TBL] [Abstract][Full Text] [Related]
20. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.
Pavet V; Beyrath J; Pardin C; Morizot A; Lechner MC; Briand JP; Wendland M; Maison W; Fournel S; Micheau O; Guichard G; Gronemeyer H
Cancer Res; 2010 Feb; 70(3):1101-10. PubMed ID: 20103630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
